MALI
MALI Platform
AI Stock Research

RTW Investments, LP: latest 13F holdings

For the quarter ending 30 September 2026, RTW Investments, LP reported 83 positions worth $9.9B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.7B.

Read the filing at SEC EDGAR
Checked: the cover page's entry count and total value match the holdings table.

Top 50 positions by value

#IssuerClassValueWeightSharesvs quarter before
1PROTAGONIST THERAPEUTICS INCCOM$713.1M7.19%5,061,175Unchanged
2ARGENX SESPONSORED ADR$682.3M6.88%711,584Added 0.3%
3CG ONCOLOGY INCCOM$603.6M6.08%8,514,590Unchanged
4IRHYTHM HOLDINGS INCCOM$354.5M3.57%3,118,913Added 42.9%
5INSMED INCCOM PAR $.01$353.4M3.56%3,096,545Cut 36.1%
6TANGO THERAPEUTICS INCCOM$350.5M3.53%14,048,477Added 1.1%
7ERASCA INCCOM$329.1M3.32%22,446,754Added 25.1%
8SPYRE THERAPEUTICS INCCOM NEW$328.7M3.31%3,691,791Cut 13.2%
9RADNET INCCOM$319.2M3.22%4,630,697Cut 4.5%
10TARSUS PHARMACEUTICALS INCCOM$273.9M2.76%3,484,066Added 3.8%
11ZAI LAB LTDADR$272.6M2.75%10,350,973Added 57.5%
12REPLIGEN CORPCOM$266.3M2.68%1,385,398Added 11.7%
13GUARDANT HEALTH INCCOM$264.2M2.66%1,481,033Unchanged
14CELCUITY INCCOM$262.8M2.65%3,304,903Unchanged
15ORUKA THERAPEUTICS INCCOM$261.4M2.64%3,139,030Unchanged
16NATERA INCCOM$248.0M2.50%600,000Cut 40.0%
17CYTOKINETICS INCCOM NEW$188.6M1.90%2,862,003Unchanged
18UROGEN PHARMA LTDCOM$184.6M1.86%4,543,895Unchanged
19ESTABLISHMENT LABS HLDGS INCCOM$171.1M1.72%2,665,695Added 0.4%
20XENCOR INCCOM$170.3M1.72%6,827,461Added 0.7%
21MADRIGAL PHARMACEUTICALS INCCOM$157.6M1.59%312,817Cut 84.3%
22IMMUNOCORE HLDGS PLCADS$147.5M1.49%4,869,798Unchanged
23STOKE THERAPEUTICS INCCOM$146.2M1.47%5,623,525Unchanged
24ACADIA PHARMACEUTICALS INCCOM$144.0M1.45%7,144,524Unchanged
25KODIAK SCIENCES INCCOM$141.1M1.42%1,487,934Unchanged
26GH RESEARCH PLCORDINARY SHARES$139.3M1.40%5,933,815Unchanged
27COMPASS PATHWAYS PLCSPONSORED ADS$136.2M1.37%10,948,591Added 2.3%
28NEUROCRINE BIOSCIENCES INCCOM$133.7M1.35%942,684Cut 25.7%
29ULTRAGENYX PHARMACEUTICAL INCOM$128.2M1.29%8,529,394Added 9.4%
30KAILERA THERAPEUTICS INCCOMMON STOCK$123.1M1.24%10,776,820Unchanged
31BELITE BIO INCSPONSORED ADS$121.5M1.22%715,332Unchanged
32IMMATICS N.VSHS$118.7M1.20%13,521,551Added 4.4%
33REPLIMUNE GROUP INCCOM$112.4M1.13%8,491,525Added 14.6%
34IMMUNOVANT INCCOM$107.3M1.08%3,177,849Unchanged
35PTC THERAPEUTICS INCCOM$104.7M1.06%1,615,819Cut 79.1%
36VIRIDIAN THERAPEUTICS INCCOM$101.1M1.02%4,910,126New
37CASTLE BIOSCIENCES INCCOM$98.7M0.99%2,778,335Unchanged
38UNIQURE NVSHS$95.2M0.96%3,941,572Unchanged
39COGENT BIOSCIENCES INCCOM$73.9M0.75%2,309,021Unchanged
40STRUCTURE THERAPEUTICS INCSPONSORED ADS$71.4M0.72%2,282,138Added 42.0%
41AXOGEN INCCOM$69.6M0.70%1,659,376Added 64.0%
42TAYSHA GENE THERAPIES INCCOM SHS$66.0M0.67%13,560,258Unchanged
43ORCHESTRA BIOMED HLDGS INCCOM$59.4M0.60%9,556,063Unchanged
44VERASTEM INCCOM NEW$54.1M0.55%6,718,081Added 1.2%
45DANAHER CORP DELCOM$51.0M0.51%230,000Unchanged
46HINGE HEALTH INCCL A$48.6M0.49%500,000Unchanged
47ROCKET PHARMACEUTICALS INCCOM$46.5M0.47%17,687,772Unchanged
48SOLID BIOSCIENCES INCCOM NEW$42.7M0.43%5,905,426Added 51.7%
49NEUROGENE INCCOM$42.1M0.42%1,512,456Added 11.0%
50CULLINAN THERAPEUTICS INCCOM$36.3M0.37%2,364,347Unchanged

Showing the largest 50 of 83 positions. Every position is in MALI's SEC Financials & 13F workspace.

New this quarter

  • VIRIDIAN THERAPEUTICS INC · $101.1M

Sold out

  • ALKERMES PLC · was $87.6M
  • DEFINIUM THERAPEUTICS INC · was $18.8M
  • IDEAYA BIOSCIENCES INC · was $13.8M
  • ATAIBECKLEY INC · was $10.5M
  • TENAX THERAPEUTICS INC · was $10.1M
  • PERCEPTIVE CAP SOLUTIONS COR · was $8.1M
  • WAVE LIFE SCIENCES LTD · was $7.8M
  • 4D MOLECULAR THERAPEUTICS IN · was $6.3M
  • MAZE THERAPEUTICS INC · was $6.3M
  • AVALO THERAPEUTICS INC · was $3.2M

Reading a 13F

A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.

Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.

Other managers